| Literature DB >> 31749696 |
Valentina Murtaj1,2, Sara Belloli2,3, Giuseppe Di Grigoli2,3, Maria Pannese4, Elisa Ballarini5,6, Virginia Rodriguez-Menendez5,6, Paola Marmiroli5,6, Andrea Cappelli7, Valeria Masiello2, Cristina Monterisi6, Giuseppe Bellelli8, Paola Panina-Bordignon4,9, Rosa Maria Moresco2,6.
Abstract
Aging is associated with an exaggerated response to peripheral inflammatory challenges together with behavioral and cognitive deficits. Studies considering both age and sex remain limited, despite sex dimorphism of astrocytes and microglial cells is largely recognized. To fill this knowledge gap, we investigated the effect of a single intraperitoneal lipopolysaccharide (LPS) administration in adult and aged mice. We assessed the expression of different inflammatory mediators, and the microglial response through binding of [18F]-VC701 tracer to translocator protein (TSPO) receptors in the male and female brain. Aged female brain showed a higher pro-inflammatory response to LPS compared to adult female and to aged male, as revealed by ex vivo binding to TSPO receptors and pro-inflammatory mediator transcript levels. The highest astroglial reaction was observed in the brain of aged females. Differently to the other groups of animals, in aged males LPS challenge did not affect transcription of triggering receptor expressed on myeloid cells 2 (TREM2). In conclusion, our study shows that in the mouse's brain the neuro-inflammatory response to an acute peripheral insult is sex- and age-dependent. Moreover, our results might set the basis for further studies aimed at identifying sex-related targets involved in the modulation of the aberrant neuro-inflammatory response that characterizes aging. This knowledge could be relevant for the treatment of conditions such as delirium and dementia.Entities:
Keywords: 18 kDa translocator protein; aging; astrocytes; microglia; neuroinflammation; triggering receptor expressed on myeloid cells 2
Year: 2019 PMID: 31749696 PMCID: PMC6848890 DOI: 10.3389/fnagi.2019.00299
Source DB: PubMed Journal: Front Aging Neurosci ISSN: 1663-4365 Impact factor: 5.750
Age, body weight, sample size and treatment dosage of each experimental group.
| Experimental group | Age | Body weight (g) | [18F]-VC701 binding ( | RT-PCR ( | IHC ( | Dosage (LPS/vehicle) |
|---|---|---|---|---|---|---|
| Adult males + LPS | 2 months | 26.9 ± 2.7 | 8 | 5/8 | 3 | 0.63 mg/kg |
| Adult males vehicle | 2 months | 26.1 ± 1.6 | 8 | 5/8 | 3 | 50 μl saline |
| Adult females + LPS | 2 months | 18.3 ± 3.6 | 8 | 4/8 | 3 | 0.63 mg/kg |
| Adult females vehicle | 2 months | 19.6 ± 1.1 | 8 | 5/8 | 3 | 30 μl saline |
| Aged males + LPS | 17/18 months | 35.5 ± 2.5 | 8 | 5/8 | 3 | 0.63 mg/kg |
| Aged male vehicle | 17/18 months | 36.4 ± 3.3 | 8 | 5/8 | 3 | 50 μl saline |
| Aged females + LPS | 17/18 months | 31.1 ± 4.2 | 8 | 5/8 | 3 | 0.63 mg/kg |
| Aged females vehicle | 17/18 months | 34.2 ± 6.6 | 8 | 5/8 | 3 | 50 μl saline |
Figure 1Schematic diagram of the experimental design and readouts.
Genes and relative primer list used in gene expression analysis.
| Name | Primer sequence (5′-3′) |
|---|---|
| 5′-gactcctatgtgggtgacgagg-3′ | |
| 5′ catggctggggtgttgaaggtc-3′ | |
| 5′-gcacctccaggaatcaagag-3′ | |
| 5′-gggtccagtgaggatctgaa-3′ | |
| 5′-tggtggtggtgttgacatttcttcc-3′ | |
| 5′atccagggtttagcatagttgctgc-3′ | |
| 5′-tcagcggctaccaacct-3′ | |
| 5′-caggattcaggcatggtgat-3′ | |
| 5′-gcccatcctctgtgactcat-3′ | |
| 5′-aggccacaggtattttgtcg-3′ | |
| 5′-cctgtagcccacgtcgtag-3′ | |
| 5′-gggagtagacaaggtacaaccc-3′ | |
| 5′-tcaacccccagctagttgtc-3′ | |
| 5′-tgttcttcgttgctgtgagg-3′ | |
| 5′-ttgggtggatgctcacactg-3′ | |
| 5′-gtacacgatgtctttggcaga-3′ | |
| 5′-agttgccttcttgggactga-3′ | |
| 5′-tccacgatttcccagagaac-3′ |
Figure 2Translocator protein (TSPO) tracer uptake reveal microglial activation increased in aged female lipopolysaccharide (LPS)-treated animals. [18F]-VC701 brain tracer uptake in cortex (A); hippocampus (B) and cerebellum (C) on LPS-treated adult and aged male and female mice. Data were analyzed using two-way ANOVA analysis with Tukey post hoc and are expressed as percentage (%) of injected dose per gram of tissue to blood ratio, mean ± SD, eight mice per group; Mouse brain stained slices (cortex, hippocampus and cerebellum) derived from immunohistochemistry (IHC) studies. *p < 0.05; **p < 0.01; ***p < 0.001.
Tissue to blood [18F]-VC701 uptake ratio.
| Brain Region | Tissue/blood ratio (%I.D./g; mean ± SD) | |
|---|---|---|
| LPS-treated adult females | LPS-treated aged females | |
| Cortex | 1.6 ± 0.6 | 2.52 ± 0.7 |
| Hippocampus | 2.31 ± 1.4 | 2.46 ± 0.9 |
| Cerebellum | 2.75 ± 1.3 | 3.75 ± 1.1 |
Figure 3Increased expression levels of pro-inflammatory cytokines in aged LPS treated mice. Gene expression analysis of IL-1β (A), TNF-α (B) and IL-6 (C) by RT-qPCR in cortex, hippocampus and cerebellum of all LPS-treated animals. All the values were normalized to mouse β-actin and expressed as fold change referred to internal control group. Bars represent the average of triplicate measurements and error bars represent ± SEM, five animals per group. Statistical analysis was performed using two-way ANOVA following by Tukey post hoc test of the relative mRNA expression of LPS-treated mice previously normalized to internal control group. *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 4Triggering receptor expressed on myeloid cells like 2 (TREM2) is differentially expressed in aged LPS treated mice. Gene expression analysis of TREM2 (A), TREML2 (B), two immunomodulatory markers by RT-qPCR in cortex, hippocampus and cerebellum of all LPS-treated animals. All the values were normalized to mouse β-actin and expressed as fold change referred to internal control group. Bars represent the average of triplicate measurements and error bars represent ± SEM, five animals per group. Statistical analysis was performed using two-way ANOVA following by Tukey post hoc test of the relative mRNA expression of LPS-treated mice previously normalized to internal control group. *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 5Increased IBA1 immunoreactivity and changes in glia morphology in brain areas of LPS-treated aged vs. LPS-treated adult females. (A) Immunostaining of Iba-1+ cells in cerebral cortex, hippocampus and cerebellum from one representative vehicle and one representative LPS-treated adult female mouse. (B) Immunostaining of Iba-1+ cells in cerebral cortex, hippocampus and cerebellum from one representative vehicle and one representative LPS-treated aged female mouse. (C) Quantification of the percentage of Iba-1+ cells in cortex, hippocampus and cerebellum of all female groups used in the study. Data are expressed as mean ± SEM of selected region of interest (ROI) performed on three animals per group, scale bar = 100 μm. *p < 0.05; **p < 0.01; ***p < 0.001.
Figure 6Increased astrocytosis and changes in glia morphology in brain areas of LPS-treated and vehicle-treated aged females. (A) Immunostaining of GFAP+ cell in cerebral cortex, hippocampus and cerebellum from one representative vehicle and one representative LPS-treated adult female mouse. (B) Immunostaining of GFAP+ astrocyte cells in cerebral cortex, hippocampus and cerebellum from one representative vehicle and one representative LPS-treated aged female mouse. (C) Quantification of percentage of GFAP+ cells in cortex, hippocampus and cerebellum of all female groups used in the study. Data are expressed as mean ± SEM of selected ROI performed on three animals per group, scale bar = 100 μm. *p < 0.05; ** p < 0.01; ***p < 0.001.